NBG
ENTA icon

Nancy B. Gardiner’s Enanta Pharmaceuticals ENTA Stock Holding History

Nancy B. Gardiner’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-16,645
Closed -$1.41M – 68
2019
Q2 		$1.41M Buy
+16,645
New +$1.5M 2.29% 17

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Nancy B. Gardiner's ENTA Position: Q3 2019 in Review

Nancy B. Gardiner sold out of Enanta Pharmaceuticals (ENTA) in Q3 2019, closing a stake of 16,645 shares — an estimated $1.41M sold.

Nancy B. Gardiner first reported a position in ENTA in Q2 2019 and held it in 1 quarter. The position peaked at $1.41M in Q2 2019. 176 funds tracked by Wall St. Rank hold ENTA as of Q3 2019.

  • Nancy B. Gardiner reported no remaining Enanta Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Nancy B. Gardiner sold 16,645 Enanta Pharmaceuticals shares in Q3 2019, an estimated $1.41M.
  • Nancy B. Gardiner first reported a position in Enanta Pharmaceuticals in Q2 2019 and held it in 1 quarter.
  • Nancy B. Gardiner's Enanta Pharmaceuticals position peaked at $1.41M in Q2 2019.
  • 176 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2019.

Based on Nancy B. Gardiner's 13F filing for Q3 2019, filed 6 Nov 2019.